Labor Day flew by and then summer faded into fall without a word from TG Therapeutics (TGTX) about the outcome of its most important blood cancer drug clinical trial. Results were way past due.
On Tuesday, we learned the reason for the long delay. TG Therapeutics needed all that extra time to gin up an excuse to paper over what is a significant setback and likely failure of its most advanced pipeline effort.
About the Author Reprints
